New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...

Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...

In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association. In the US, ...

A new report from the American Lung Association reveals that Georgia ranks among the worst states in the nation for lung ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

November is Lung Cancer Awareness Month, which is the leading cause of cancer-related deaths among both men and women.

Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage ...

Chemoradiotherapy (CRT) was preferred to radiotherapy alone in patients older than 65 years who had stage II nonsurgical non–small cell lung cancer (NSCLC), as overall survival (OS) and ...

According to the NCCN Guidelines for metastatic lung cancer, standard therapies remain valuable, but they are no longer sufficient on their own. This is why molecular profiling, targeted therapy, and ...